{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:51:41Z","timestamp":1772844701997,"version":"3.50.1"},"reference-count":79,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,3,16]]},"DOI":"10.1080\/14796694.2025.2466416","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:46:56Z","timestamp":1740469616000},"page":"867-878","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2787-0271","authenticated-orcid":false,"given":"S\u00f8ren Paaske","family":"Johnsen","sequence":"first","affiliation":[{"name":"Aalborg University and Aalborg University Hospital","place":["Gistrup, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[{"name":"Netherlands Cancer Institute","place":["Amsterdam, The Netherlands"]},{"name":"Leiden University Medical Hospital","place":["Leiden, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Benn","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Rigshospitalet","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Intercommunal de Cr\u00e9teil","place":["Cr\u00e9teil, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[{"name":"Pius-Hospital, University Medicine Oldenburg","place":["Oldenburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda J","family":"Daumont","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Braine-L\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Rault","sequence":"additional","affiliation":[{"name":"Data Gnosis","place":["Rennes, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Emanuel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Uxbridge, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R","family":"Penrod","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazel","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Syneos Health","place":["Farnborough, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Muwaffak","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Ltd","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minouk J","family":"Schoemaker","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Ltd","place":["Amsterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin EJ","family":"Munro","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Ltd","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshan","family":"Baskaran","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA Ltd","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Durand-Zaleski","sequence":"additional","affiliation":[{"name":"UPEC","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_6_4_1","unstructured":"GLOBOCAN. Europe fact sheets [Internet]. 2022 [cited 2025 Feb 5]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/908-europe-fact-sheet.pdf"},{"key":"e_1_3_6_5_1","unstructured":"GLOBOCAN. North America fact sheets [Internet] 2022 [cited 2025 Feb 5]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/905-northern-america-fact-sheet.pdf"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00444-8"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.008"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx222"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1994"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03022"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03570"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02528"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00051"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01435"},{"key":"#cr-split#-e_1_3_6_20_1.1","unstructured":"PDQ\u00ae Adult Treatment Editorial Board. PDQ malignant mesothelioma treatment. Bethesda (MD): National Cancer Institute. [Updated 2024 Apr 24"},{"key":"#cr-split#-e_1_3_6_20_1.2","unstructured":"cited 2024 Oct 23]. Available from: https:\/\/www.cancer.gov\/types\/mesothelioma\/hp\/mesothelioma-treatment-pdq"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.12.023"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071414"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01896-x"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-3034"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02985-6"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33984"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09750-7"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0591"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.01.012"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0025"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01270-z"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13496"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2217\/lmt-2020-0028"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.11.001"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046396"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043442"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100165"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0746"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09342-5"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246148"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.08.001"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02288-1"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-176"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091655"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0480"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.04.017"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000857"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.1145"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.2419"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.71"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1746"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104618"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.34802"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.459"},{"key":"e_1_3_6_55_1","unstructured":"ESMO. ESMO Oncology News: EMA recommends extension of therapeutic indications for atezolizumab. 2022. [cited 2024 Jul 15]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-therapeutic-indications-for-atezolizumab"},{"key":"e_1_3_6_56_1","unstructured":"ESMO. ESMO Oncology News: EMA recommends extension of indications for nivolumab. 2023. [cited 2024 Jul 15]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-nivolumab2"},{"key":"e_1_3_6_57_1","unstructured":"ESMO. ESMO Oncology News: EMA recommends extending indications for pembrolizumab to include adjuvant treatment in NSCLC. 2023. [cited 2024 Jul 15]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extending-indications-for-pembrolizumab-to-include-adjuvant-treatment-in-nsclc"},{"key":"e_1_3_6_58_1","unstructured":"ESMO. EMA recommends extension of indications for alectinib to adjuvant treatment of resected ALK-positive NSCLC. 2024. [cited 2024 Oct 23]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-alectinib-to-adjuvant-treatment-of-resected-alk-positive-nsclc"},{"key":"e_1_3_6_59_1","unstructured":"U.S. Food & Drug Administration. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. 2022. [cited 2024 Oct 23]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung"},{"key":"e_1_3_6_60_1","unstructured":"U.S. Food & Drug Administration. FDA approves neoadjuvant\/adjuvant pembrolizumab for resectable non-small cell lung cancer. 2023. [cited 2024 Oct 23]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer"},{"key":"e_1_3_6_61_1","unstructured":"U.S. Food & Drug Administration. FDA approves neoadjuvant\/adjuvant nivolumab for resectable non-small cell lung cancer. 2024. [cited 2024 Oct 23]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvantadjuvant-nivolumab-resectable-non-small-cell-lung-cancer"},{"key":"e_1_3_6_62_1","unstructured":"U.S. Food & Drug Administration. FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer. 2024. [cited 2024 Oct 23]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2363133"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.1361"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1041"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01319-8"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70049"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.003"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02715-8"},{"key":"e_1_3_6_70_1","unstructured":"Innovative Medicines Initiative. GETREAL: incorporating real-life clinical data into drug development. [cited 2024 Jul 15]. Available from: https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/getreal"},{"key":"e_1_3_6_71_1","unstructured":"European Medicines Agency. Data Analysis and Real World Interrogation Network (DARWIN EU). [cited 2023 May 4]. Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/big-data\/data-analysis-real-world-interrogation-network-darwin-eu"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.003"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221122720"},{"key":"e_1_3_6_74_1","unstructured":"HARMONY Alliance. Big Data Platform. 2023. [cited 2024 Jul 15]. Available from: https:\/\/www.harmony-alliance.eu\/bigdata-platform\/big-data-platform"},{"key":"e_1_3_6_75_1","unstructured":"HARMONY Alliance. Databarometer. 2023. [cited 2024 Jul 15]. Available from: https:\/\/www.harmony-alliance.eu\/bigdata-platform\/databarometer"},{"key":"e_1_3_6_76_1","unstructured":"National Institute for Health and Care Excellence. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma: technology appraisal guidance. 2022. [cited 2024 Jul 15]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta818\/resources\/nivolumab-with-ipilimumab-for-untreated-unresectable-malignant-pleural-mesothelioma-pdf-82613317073605"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4932"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2461"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.18433\/jpps32715"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3018"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2466416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:36:31Z","timestamp":1762958191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2466416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,3,16]]}},"alternative-id":["10.1080\/14796694.2025.2466416"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2466416","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}